Briciclib (sodium)

• Description :

  Briciclib (ON 014185) sodium is a eukaryotic translation initiation factor 4E (eIF4E) inhibitor. Briciclib sodium exhibits broad-spectrum anti-cancer activity, including in mantle cell leukemia, breast cancer, gastric cancer, and esophageal cancer cells. Briciclib sodium reduces the expression of cyclin D1 and c-Myc, and enhances the expression of P53 and Cleaved Caspase 3 pro-apoptotic proteins. Briciclib sodium can be used for the study of hematological system tumors and solid tumors[1].

• Product Name Alternative :

  ON 014185 (sodium)

• UNSPSC :

  12352005

• Target :

  Apoptosis; Caspase; CDK; c-Myc; Eukaryotic Initiation Factor (eIF) ; MDM-2/p53

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Smiles :

  O=S(CC1=CC(OP(O[Na])(O[Na])=O)=C(OC)C=C1)(/C=C/C2=C(OC)C=C(OC)C=C2OC)=O

• Molecular Formula :

  C19H21Na2O10PS

• Molecular Weight :

  518.38

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [865784-01-6]